PEMBROLIZUMAB

Brand name:

• Keytruda®

Pharmaceutical company:

Merck Sharp & Dohme (Australia) Pty Ltd

Condition/indication:
(therapeutic use)

• Non-small cell lung cancer (NSCLC)

PBAC Submission type:

Change to listing (Major)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – July 2019

Related medicines:

--

Submission received for:

July 2019 PBAC meeting

Opportunity for consumer comment:

Open 01/05/2019 and close 12/06/2019 (see PBS Website)

PBAC meeting:

Held on 10/07/2019

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

09/08/2019

Lodgement of required documentation:

16/08/2019

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 22/08/2019

Status:

Finalised

Government processes:

Commenced on 25/10/2019

Medicine listed on the PBS:

01/12/2019 (see PBS schedule)

---